Myriad Genetics Inc. (MYGN)
Loading...
Symbols:
MYGN Forum Topics
- All Comments on MYGN
- General Discussion on MYGN
- Will Myriad Genetics Keep Its Momentum? [view article]
- Cancer Stocks Plunge Following ASCO Meeting [view article]
- Myriad Genetics: I Told You So [view article]
- Ten Ways to Invest in Utah [view article]
- Myriad Genetics, Inc. F4Q08 (Qtr End 06/30/08) Earnings Call Transcript [view article]
- In Tech We Trust - Fast Money Recap (6/20/08) [view article]
- Cancer Stocks on the Go: Winners and Losers [view article]
- GM an Unlikely Hero - Fast Money Recap (7/1/08) [view article]
- Myriad Genetics: Another Alzheimer's Compound Goes Down [view article]
- Will Wal-Mart Heat Up Chile? Fast Money (6/17/08) [view article]
- Myriad Options on Alzheimers Disease [view article]
- Friday Options Outlook (Update): SOLF, TIN, MYGN, MSFT, DNA, DRYS, HRS, DO, JCG, HHH [view article]
loading ...Recent MYGN Articles
- Myriad Genetics Spin-Off Would Be a Welcome Move
- Weekly Insider Buying/Selling Wrap and Economic Reports Preview
- Ten Ways to Invest in Utah
- Will Myriad Genetics Keep Its Momentum?
- GM an Unlikely Hero - Fast Money Recap (7/1/08)
- Myriad Genetics: I Told You So
- Monday Options Update: C, MYGN, TSN, LLTC, F, GM, BEC, RNWK
- Myriad Genetics: Another Alzheimer's Compound Goes Down
- Bernanke, the Greatest Speculator - Fast Money (6/25/08)
- BioMarin, Myriad, and Regeneron Show a Quiet Strength
- Full List of Articles »
Trading Center
Hedge Fund Jobs
Job Seekers: Search jobs by category, get job alerts by email or live feed, apply online See full list of jobs »
Employers: See all recruitment options, get applications online or by email Post a job »
Schweitzer
Myriad Options on Alzheimers Disease [view article]
You might also look at the work of CLN ReplyMyriad Options on Alzheimers Disease [view article]
To Mudphud (I guess that is an acronym for MD PhD):Your point about naproxen and celecoxib and their ineffectiveness in mouse models is true. However, as you point out in the part of the article that you pasted, ibuprofen does lower Aβ42. But ibuprofen, as cited by the authors of the ADAPT study, was not effective in a trial (Goodwin JS, Regan M. Cognitive dysfunction associated with naproxen and ibuprofen in the elderly. Arthritis Rheum. 1982;25(8):1013-1015).
Other studies have also shown ineffectiveness of NSAIDS (Karplus TM, Saag KG. Nonsteroidal anti-inflammatory drugs and cognitive function: do they have a beneficial or deleterious effect? Drug Saf. 1998;19(6):427-433).
To be fair, I must also point out that some studies have shown a beneficial effect (Rozzini R, Ferrucci L, Losonczy K; et al. Protective effect of chronic NSAID use on cognitive decline in older persons. J Am Geriatr Soc. 1996;44(9):1025-1029.)
However - from a commercial point of view, and therefore from a stock point of view, two things remain:
1. What is the effect of Flurizan? The phase II data was less than stellar, and I make it very clear in my article that the ADAPT study is not identical but gives hints.
2. If other anti-inflammatories have the same effect as Flurizan, why would anyone take Flurizan when cheap generics would have the same effect?
So that other readers can make their own minds, I'm pasting a link to the cited article:
archneur.ama-assn.org/...
Reply
Myriad Options on Alzheimers Disease [view article]
Some of the scientific info in this post is wrong. The naproxen and celebrex trial were designed to test the affect of COX inhibition on alzheimer's disease, since naproxen and celebrex do NOT inhibit gamma secretase.The Archives of Neurology article cited in this post say it best:
"It may be that the ADAPT findings relate specifically to celecoxib or naproxen, perhaps because these drugs are not among those NSAIDs that have been shown in vitro and in vivo in mouse models to lower production of the 42-residue form of amyloid β (Aβ42)21; that is, the epidemiological findings could be due to the effects of other NSAIDs, such as the commonly used ibuprofen, that do lower Aβ42. More speculatively, the ADAPT findings may represent early detrimental effects following initiation of treatment in people who have subclinical neuropathology. That is, NSAIDs might exert protective effects only if given several years before the time when symptoms would otherwise develop. Such a difference in effect has been suggested by results of both the Rotterdam22 and Cache County23 observational studies, which showed apparent protective effects with more distant, but not recent, use of NSAIDs." Reply
Tiedeman
Five Biotech Stocks to Weather a Down Market [view article]
DNDN has all the risk, but all the reward too. I think the FDA says yes this time. At least for the very latest stage of the prostate menace. ReplyFast Money Recap, 4/9/08: Airlines MayTake Off [view article]
Anyone who not only watches this slimiest group of touts/thieves/liars, but actually follows their recommendations, deserves to lose money.CNBC reached down into a toilet and came up with this group.
As if Cramer wasn't bad enough, this den of thieves makes Cramer look sainted.
Reply
Fast Money Recap, 4/7/08: Is Energy Topping? [view article]
The stock market is just so unpredictable at the moment. I will wait on the sidelines until all this "madness" passes. ReplyEditors
General Discussion on MYGN
Is this a buy or a sell? ReplyCancer Stocks Hammered Once Again [view article]
Alan,What are your thoughts on Chemokine Therapeutics Corp (CHKT)?
And Meridian Co LTD (MRDAF)?
Reply
Cancer Stocks Hammered Once Again [view article]
please ignore the comment above. it was posted in the wrong thread.Reply
Cancer Stocks Hammered Once Again [view article]
Maybe BofA should by this one too.Which bank took the highly rated debt at a discount from TMA? Reply
Brochstein
Cancer Stocks Hammered Once Again [view article]
I don't know the company, but it sure looks interesting. Technically, it would be nice to hold 1.75. The company is seemingly deficient in cash - it would appear that there will be either an equity or debt offering this year. If they become profitable as forecast this year, the stock could get some attention - diagnostics have been hot. ReplyCancer Stocks Hammered Once Again [view article]
Hi Alan,What is your current opinion on Clarient (CLRT)?
Thanks very much,
Don Reply
Expect Pressure on Myriad Genetics Following Trial News [view article]
Notable: I agree with your assessment. AD is a slippery slope under the best of circumstances. Additionally, I understand the drugs' side effect profile has been underwhelming, but this is anecdotal, and remember these are brittle patients. Bottom line, expect MYGN's valuation to become more volatile the closer it gets to releasing the phase data. I actually think that statistically, Elan's 2nd generation AD vaccine, as well as DNDN's Provenge have a better chance of reaching the market. Disclosure: I am long DNDN, do not have positions in Elan or MYGN. I am a former Elan employee. ReplyBrochstein
Cancer Stocks Hammered Once Again [view article]
Thanks for the comment and the compliment. Thanks also for the information. Contact me by phone or email if you would like to discuss your ideas. ReplyCancer Stocks Hammered Once Again [view article]
Great post! It would be quite useful if your excel file could be downloaded, then someone could sort on other attributes, or even add some, e.g. #drugs in phase 3, total #drugs in pipeline, #big pharma collaborations, PADUFA dates, if any, etc. I'm offering a few comments vis-à-vis individual companies: I think EXEL, which probably has the deepest pipeline on your list, is gaining because investors believe Glaxo will take XL647. I believe it's, "show's over", for TELK (Telcyta is finito). Onyx is declining because it faces stiff competition from Pfizer's Sutent & now Wyeth's Torisol in renal cell carcinoma. Any sales increases for Onyx's Nexavar will come from off-label use in liver cancer, but that is not, in my opinion, a reason to invest. CEGE's recent decline is a gift - when European Revlimid sales appear on their balance sheet, along with clinical milestone press releases, it'll get back into the 60's. GNTA has been on a slippery slope for some time now - their CEO, Ray Warrell, is very smart, very committed, and held in high regard by his oncology peers at his alma mater, MSKCC. He is making use of FDA's dispute process for Genasense in CLL, so some investors are betting FDA will offer up a conditional approval in subsets of patients. The key here is that CLL is a very heterogeneous disease - therapy needs to be more individualized. Finally, in my opinion, ISRG is absolutely the future of surgery. Any decline into the low 130's is a bargain. Thanks again for your article! Reply